Citadel Advisors LLC Makes New $31,000 Investment in Context Therapeutics Inc. (NASDAQ:CNTX)

Citadel Advisors LLC purchased a new stake in Context Therapeutics Inc. (NASDAQ:CNTX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 29,900 shares of the company’s stock, valued at approximately $31,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Allostery Investments LP purchased a new stake in shares of Context Therapeutics in the 4th quarter valued at approximately $998,000. Jane Street Group LLC purchased a new stake in shares of Context Therapeutics in the 4th quarter valued at approximately $29,000. Blue Owl Capital Holdings LP raised its stake in shares of Context Therapeutics by 17.5% in the 4th quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company’s stock valued at $6,676,000 after acquiring an additional 946,638 shares during the period. Marshall Wace LLP purchased a new stake in shares of Context Therapeutics in the 4th quarter valued at approximately $213,000. Finally, Walleye Capital LLC raised its stake in shares of Context Therapeutics by 51.7% in the 4th quarter. Walleye Capital LLC now owns 166,306 shares of the company’s stock valued at $175,000 after acquiring an additional 56,651 shares during the period. 14.03% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Jennifer Lynn Minai-Azary purchased 40,010 shares of the stock in a transaction on Friday, June 6th. The stock was bought at an average price of $0.64 per share, for a total transaction of $25,606.40. Following the acquisition, the chief financial officer now directly owns 80,010 shares of the company’s stock, valued at approximately $51,206.40. The trade was a 100.03% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Martin A. Lehr bought 100,000 shares of the stock in a transaction dated Monday, June 9th. The stock was bought at an average price of $0.70 per share, with a total value of $70,000.00. Following the acquisition, the chief executive officer now owns 920,190 shares in the company, valued at approximately $644,133. This represents a 12.19% increase in their position. The disclosure for this purchase can be found here. Insiders bought 160,010 shares of company stock worth $107,206 in the last 90 days. Corporate insiders own 2.80% of the company’s stock.

Context Therapeutics Stock Up 5.2%

Shares of CNTX opened at $0.65 on Friday. Context Therapeutics Inc. has a fifty-two week low of $0.49 and a fifty-two week high of $2.75. The firm’s 50 day moving average price is $0.75 and its 200 day moving average price is $0.91. The company has a market cap of $58.54 million, a P/E ratio of -0.72 and a beta of 1.86.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). Research analysts forecast that Context Therapeutics Inc. will post -0.51 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on CNTX. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Context Therapeutics in a research note on Friday, March 21st. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research note on Thursday, May 8th. Finally, William Blair reaffirmed an “outperform” rating on shares of Context Therapeutics in a research note on Tuesday, April 29th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $6.00.

Context Therapeutics Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.